MAP2K1 and cystic fibrosis: While the MEK1 inhibitor had a barely noticeable effect and only at its highest dose in both cell types (Figure 7A), the JNK inhibitor appeared to be an equally potent blocker of CF-induced IL-6 secretion in BMDM from wild-type and CD36-KO mice (Figure 7B).